Marzyeh Ghassemi1, John Marshall2, Nakul Singh3, David J Stone4, Leo Anthony Celi5. 1. Massachusetts Institute of Technology, Cambridge, MA. 2. Beth Israel Deaconess Medical Center, Boston, MA. 3. Harvard School of Public Health, Boston, MA. 4. University of Virginia School of Medicine, Charlottesville, VA. 5. Massachusetts Institute of Technology, Cambridge, MA; Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: lceli@bidmc.harvard.edu.
Abstract
BACKGROUND: Observational studies have found an increased risk of adverse effects such as hemorrhage, stroke, and increased mortality in patients taking selective serotonin reuptake inhibitors (SSRIs). The impact of prior use of these medications on outcomes in critically ill patients has not been previously examined. We performed a retrospective study to determine if preadmission use of SSRIs or serotonin norepinephrine reuptake inhibitors (SNRIs) is associated with mortality differences in patients admitted to the ICU. METHODS: The retrospective study used a modifiable data mining technique applied to the publicly available Multiparameter Intelligent Monitoring in Intensive Care (MIMIC) 2.6 database. A total of 14,709 patient records, consisting of 2,471 in the SSRI/SNRI group and 12,238 control subjects, were analyzed. The study outcome was in-hospital mortality. RESULTS: After adjustment for age, Simplified Acute Physiology Score, vasopressor use, ventilator use, and combined Elixhauser score, SSRI/SNRI use was associated with significantly increased in-hospital mortality (OR, 1.19; 95% CI, 1.02-1.40; P=.026). Among patient subgroups, risk was highest in patients with acute coronary syndrome (OR, 1.95; 95% CI, 1.21-3.13; P=.006) and patients admitted to the cardiac surgery recovery unit (OR, 1.51; 95% CI, 1.11-2.04; P=.008). Mortality appeared to vary by specific SSRI, with higher mortalities associated with higher levels of serotonin inhibition. CONCLUSIONS: We found significant increases in hospital stay mortality among those patients in the ICU taking SSRI/SNRIs prior to admission as compared with control subjects. Mortality was higher in patients receiving SSRI/SNRI agents that produce greater degrees of serotonin reuptake inhibition. The study serves to demonstrate the potential for the future application of advanced data examination techniques upon detailed (and growing) clinical databases being made available by the digitization of medicine.
BACKGROUND: Observational studies have found an increased risk of adverse effects such as hemorrhage, stroke, and increased mortality in patients taking selective serotonin reuptake inhibitors (SSRIs). The impact of prior use of these medications on outcomes in critically illpatients has not been previously examined. We performed a retrospective study to determine if preadmission use of SSRIs or serotonin norepinephrine reuptake inhibitors (SNRIs) is associated with mortality differences in patients admitted to the ICU. METHODS: The retrospective study used a modifiable data mining technique applied to the publicly available Multiparameter Intelligent Monitoring in Intensive Care (MIMIC) 2.6 database. A total of 14,709 patient records, consisting of 2,471 in the SSRI/SNRI group and 12,238 control subjects, were analyzed. The study outcome was in-hospital mortality. RESULTS: After adjustment for age, Simplified Acute Physiology Score, vasopressor use, ventilator use, and combined Elixhauser score, SSRI/SNRI use was associated with significantly increased in-hospital mortality (OR, 1.19; 95% CI, 1.02-1.40; P=.026). Among patient subgroups, risk was highest in patients with acute coronary syndrome (OR, 1.95; 95% CI, 1.21-3.13; P=.006) and patients admitted to the cardiac surgery recovery unit (OR, 1.51; 95% CI, 1.11-2.04; P=.008). Mortality appeared to vary by specific SSRI, with higher mortalities associated with higher levels of serotonin inhibition. CONCLUSIONS: We found significant increases in hospital stay mortality among those patients in the ICU taking SSRI/SNRIs prior to admission as compared with control subjects. Mortality was higher in patients receiving SSRI/SNRI agents that produce greater degrees of serotonin reuptake inhibition. The study serves to demonstrate the potential for the future application of advanced data examination techniques upon detailed (and growing) clinical databases being made available by the digitization of medicine.
Authors: An Pan; Olivia I Okereke; Qi Sun; Giancarlo Logroscino; JoAnn E Manson; Walter C Willett; Alberto Ascherio; Frank B Hu; Kathryn M Rexrode Journal: Stroke Date: 2011-08-11 Impact factor: 7.914
Authors: Timothy Petersen; Christina Dording; Nicole B Neault; Rebecca Kornbluh; Jonathan E Alpert; Andrew A Nierenberg; Jerrold F Rosenbaum; Maurizio Fava Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2002-01 Impact factor: 5.067
Authors: Jordan W Smoller; Matthew Allison; Barbara B Cochrane; J David Curb; Roy H Perlis; Jennifer G Robinson; Milagros C Rosal; Nanette K Wenger; Sylvia Wassertheil-Smoller Journal: Arch Intern Med Date: 2009-12-14
Authors: Andrew D Auerbach; Eric Vittinghoff; Judith Maselli; Penelope S Pekow; John Q Young; Peter K Lindenauer Journal: JAMA Intern Med Date: 2013-06-24 Impact factor: 21.873
Authors: Leo Anthony Celi; Edward Moseley; Christopher Moses; Padhraig Ryan; Melek Somai; David Stone; Kai-Ou Tang Journal: Big Data Date: 2014-09-01 Impact factor: 2.128